Rockefeller Capital Management
RGC icon

Rockefeller Capital Management’s Regencell Bioscience RGC Stock Holding History

Rockefeller Capital Management’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.08K Buy
505
+485
+2,425% +$11.6K ﹤0.01% 4337
2026
Q1 		$509 Sell
20
-55
-73% -$1.56K ﹤0.01% 4562
2025
Q4 		$1.57K Buy
+75
New +$1.22K ﹤0.01% 4372

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Rockefeller Capital Management's RGC Position: Q2 2026 in Review

Rockefeller Capital Management increased its Regencell Bioscience (RGC) stake by 2,425% in Q2 2026, buying an estimated $11.6K and bringing the position to 505 shares worth $3.08K. The position accounts for ﹤0.01% of the portfolio, ranked #4337.

Rockefeller Capital Management first reported a position in RGC in Q4 2025 and has held it in 3 quarters since. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • Rockefeller Capital Management held 505 shares of Regencell Bioscience worth $3.08K as of Q2 2026.
  • Rockefeller Capital Management bought 485 Regencell Bioscience shares in Q2 2026, an estimated $11.6K.
  • Regencell Bioscience made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4337 holding.
  • Rockefeller Capital Management first reported a position in Regencell Bioscience in Q4 2025 and has held it in 3 quarters since.
  • 35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.